Exhaled carbon monoxide in asthmatic adults with bronchial reactivity: a prospective study

Factors influencing the levels of exhaled carbon monoxide in asthmatic children

OBJECTIVE

Bronchial asthma is characterised by chronic airway inflammation commonly associated with increased oxidative stress. Exhaled carbon monoxide (eCO) levels could act as markers of both oxidative stress and allergic inflammation. We aimed to study eCO levels in asthmatics and detect the possible factors influencing them.

METHODS

We studied 241 asthmatic children and 75 healthy children. The differences in eCO levels among various asthmatic phenotypes and the correlations between eCO and other measured parameters (spirometric indices, Asthma Control Test score, exhaled nitric oxide, total IgE, blood eosinophils and marker of oxidative damage of proteins) were analysed.

RESULTS

Levels of eCO widely differed according to the selected characteristics of asthma. Asthmatics showed higher eCO concentrations than controls (1.44 ± 0.12 ppm vs. 0.91 ± 0.11 ppm, p < 0.001). Acute exacerbation of asthma was accompanied by a significant increase in eCO compared to the clinically controlled stage (2.17 ± 0.36 ppm vs. 1.33 ± 0.13 ppm, p < 0.001). Atopic, non-atopic asthma and asthma associated with allergic rhinitis (AR) showed elevated levels of eCO. The levels of eCO negatively correlated with the marker of protein oxidation in asthmatics, especially in atopic form and during acute exacerbation.

CONCLUSIONS

In a population of asthmatic children, eCO levels could be considered as a marker of both allergic inflammation and oxidative stress in the airways. Concomitant AR and asthma control were the most important factors affecting the levels of eCO in asthmatic children. However, our results do not support the use of routine eCO in the clinical practice.

Exhaled carbon monoxide in airway diseases: from research findings to clinical relevance

Breath tests have gained increasing interest in recent years mainly driven by the unmet clinical need to monitor airway diseases and to obtain information of unravelled aspects of respiratory disorders. Carbon monoxide is present in the exhaled breath and has been suggested to reflect ongoing oxidative stress, even if there are some confounding factors limiting its clinical usefulness. Increased concentration of exhaled carbon monoxide has been demonstrated in different acute and chronic airway diseases including allergic rhinitis, asthma, bronchiectasis, and post transplant bronchiolitis obliterans syndrome. Although exhaled carbon monoxide might not prove as a clinically useful biomarker of airway diseases, its measurement has helped to understand the place of heme oxygenase activity in allergic and non-allergic airway diseases. The scope of this review is the exciting field of exhaled carbon monoxide in airway diseases.

Endogenous carbon monoxide production in disease

Carbon monoxide (CO) in tissues and cells can originate from inhalation of CO or endogenously. Endogenous production, carboxyhemoglobin (COHb) formation, and exhaled CO levels are influenced by physiological factors, including disease. It is suggested that endogenous CO production can be used as a biomarker for oxidative and inflammatory processes. Also, endogenous CO can contribute to increased body burden of CO, which may both disrupt normal CO signaling cascades and increase the risk of CO toxicity.